Tempus AI (NASDAQ: TEM) recently disclosed a multi-year strategic collaboration with Gilead Sciences to bolster precision oncology research. This partnership places Tempus AI at the…
Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine, has announced the publication of a pivotal study in JCO Precision Oncology validating the…